scholarly journals Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin

2021 ◽  
Vol 15 (1) ◽  
pp. 132-137
Author(s):  
Anwar Ali Jammah
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Insulin Aspart ◽  
Basal Insulin ◽  
Indirect Comparison ◽  
Insulin Degludec ◽  
Efficacy And Safety ◽  
Diabetes Patients

Efficacy and Safety of Once Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Patients (AWARD-2)

2014 ◽  
Vol 38 (5) ◽  
pp. S4 ◽  
Author(s):  
Francesco Giorgino ◽  
Marian Benroubi ◽  
Jui-Hung Sun ◽  
Alan G. Zimmermann ◽  
Valeria Pechtner
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Efficacy And Safety ◽  
Diabetes Patients

scholarly journals Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial

2020 ◽  
Vol 8 (1) ◽  
pp. e001518 ◽  
Author(s):  
Antonio Perez ◽  
Francisco Javier Carrasco-Sánchez ◽  
Carlos González ◽  
José Miguel Seguí-Ripoll ◽  
Carlos Trescolí ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Treatment Satisfaction ◽  
Diabetes Management ◽  
Glycosylated Hemoglobin ◽  
Insulin Regimen ◽  
Efficacy And Safety ◽  
Phase Iv

IntroductionThis study assessed the efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in insufficiently controlled people with type 2 diabetes.Research design and methodsCOBALTA (for its acronym in Spanish, COntrol Basal durante la hospitalizacion y al ALTA) was a multicenter, open-label, single-arm, phase IV trial including 112 evaluable inpatients with type 2 diabetes insufficiently controlled (glycosylated hemoglobin (HbA1c) 8%–10%) with basal insulin and/or non-insulin antidiabetic drugs. Patients were treated with a basal–bolus–correction insulin regimen with Gla-300 during the hospitalization and with Gla-300 and/or non-insulin antidiabetics for 6 months after discharge. The primary endpoint was the HbA1c change from baseline to month 6 postdischarge.ResultsHbA1c levels decreased from 8.8%±0.6% at baseline to 7.2%±1.1% at month 6 postdischarge (p<0.001, mean change 1.6%±1.1%). All 7-point blood glucose levels decreased from baseline to 24 hours predischarge (p≤0.001, mean changes from 25.1±66.6 to 63.0±85.4 mg/dL). Fasting plasma glucose also decreased from baseline to 24 hours predischarge (p<0.001), month 3 (p<0.001) and month 6 (p<0.001) postdischarge (mean changes 51.5±90.9, 68.2±96.0 and 77.6±86.4 mg/dL, respectively). Satisfaction was high and hyperglycemia/hypoglycemia perception was low according to the Diabetes Treatment Satisfaction Questionnaire at month 6 postdischarge. The incidence of confirmed (glucose<70 mg/dL)/severe hypoglycemia was 25.0% during hospitalization and 59.1% 6 months after discharge. No safety concerns were reported.ConclusionsInpatient and intensification therapy at discharge with Gla-300 improved significantly glycemic control of patients with type 2 diabetes insufficiently controlled with other basal insulin and/or non-insulin antidiabetic medication, with high treatment satisfaction. Gla-300 could therefore be a treatment choice for hospital and postdischarge diabetes management.

Sign in / Sign up

Export Citation Format

Share Document